Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Zev A. Wainberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7142-1246; OpenAlex author ID A5019473289, A5039098513; NIH RePORTER profile ID 14545921. Sources: ClinicalTrials.gov.

Their work

Papers
49 (first author 3, last author 5)
Trials
2 (principal investigator on 2)
Grants
2
Labs led
1
Collaborators
215
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers, 1 trial · 2020: 3 papers · 2021: 6 papers · 2022: 4 papers · 2023: 3 papers, 1 trial · 2024: 6 papers · 2025: 3 papers, 1 grant · 2026: 13 papers, 1 grant

Papers 49

  1. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  2. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  3. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  4. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  5. PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in panc… Co-author DOI 10.1038/s41417-026-01091-y↗
  6. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
  7. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  8. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  9. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. Last author DOI 10.1056/nejmc2611022↗
  10. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. First author DOI 10.1056/nejmoa2605555↗
  11. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Co-author DOI 10.1080/14796694.2026.2664776↗
  12. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  13. Clinical relevance of MTAP deletion in pancreatic ductal adenocarcinoma: a real-world US patient cohort study Last author DOI 10.1186/s12885-026-17215-4↗
  14. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Last author DOI 10.1016/j.esmoop.2025.105534↗
  15. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  16. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  17. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  18. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  19. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  20. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Co-author DOI 10.1038/s41571-024-00952-5↗
  21. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  22. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… First author DOI 10.3390/cancers16071323↗
  23. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Last author DOI 10.1016/j.ctrv.2022.102502↗
  24. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  25. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  26. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  27. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
  28. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1080/03007995.2022.2059976↗
  29. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2967/jnumed.121.261952↗
  30. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Co-author DOI 10.1002/advs.202002147↗
  31. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗
  32. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/psp4.12725↗
  33. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  34. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Co-author DOI 10.1016/j.ejca.2021.03.028↗
  35. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  36. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0099↗
  37. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  38. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I … Co-author DOI 10.1634/theoncologist.2020-0474↗
  39. Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001349↗
  40. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  41. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6290-8↗
  42. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. Co-author DOI 10.1172/jci92284↗
  43. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreat… First author DOI 10.1634/theoncologist.2017-0024↗
  44. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3149-4↗
  45. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. Co-author DOI 10.1016/j.jmoldx.2016.03.006↗
  46. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  47. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Co-author DOI 10.1002/jso.24011↗
  48. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗
  49. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Co-author DOI 10.1245/s10434-013-3159-3↗

Trials 2

  1. Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenoc… Principal investigator NCT05688215↗
  2. Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Principal investigator NCT03970252↗

Grants 2

  1. Causes and Consequences of Adenosine Signaling in Pancreatic Cancer R01CA290888↗
  2. Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer R01CA260678↗

Closest collaborators

The 25 strongest of 215 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 15 shared papers, 2021–2026 · strength 3.40
  2. Timothy R. Donahue · 12 shared papers, 2 shared grants, 2013–2026 · strength 3.21
  3. Caius Gabriel Radu · 1 shared paper, 2 shared grants, 2025–2026 · strength 2.06
  4. Shubham Pant · 9 shared papers, 2021–2026 · strength 1.73
  5. Teresa Mercade Macarulla · 9 shared papers, 2021–2026 · strength 1.69
  6. Tanios Bekaii‐Saab · 8 shared papers, 2021–2026 · strength 1.43
  7. Mark D. Girgis · 8 shared papers, 2016–2026 · strength 1.11
  8. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  9. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  10. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  11. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  12. Eric Van Cutsem · 5 shared papers, 2023–2026 · strength 0.99
  13. Oscar Joe Hines · 8 shared papers, 2013–2026 · strength 0.87
  14. Vincent M. Chung · 4 shared papers, 2024–2026 · strength 0.81
  15. Farshid Dayyani · 4 shared papers, 2021–2026 · strength 0.78
  16. Hassan A. Hatoum · 3 shared papers, 2026 · strength 0.73
  17. Mark H. O’Hara · 5 shared papers, 2021–2026 · strength 0.73
  18. Brian Matthew Wolpin · 2 shared papers, 2026 · strength 0.73
  19. Paul E. Oberstein · 4 shared papers, 2019–2026 · strength 0.68
  20. Andrew H. Ko · 5 shared papers, 2019–2026 · strength 0.61
  21. Jason M. Link · 3 shared papers, 2024–2026 · strength 0.60
  22. Andrew Peter Dean · 4 shared papers, 2021–2025 · strength 0.58
  23. Nathan Bahary · 3 shared papers, 2024–2026 · strength 0.58
  24. Jonathan C. King · 3 shared papers, 2021–2026 · strength 0.56
  25. Andrew Eugene Hendifar · 3 shared papers, 2023–2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.